Company Overview
Snapshot
Founded in January 2017 by Ofer Mandelboim and Pini Tsukerman, Nectin Therapeutics operates with 11–50 employees. The company has raised $36 million across 6 funding rounds from 7 investors. In May 2024, Nectin Therapeutics secured additional funding from Guangzhou Sino-Israel Biotech Investment Fund (GIBF).
Business overview
Nectin Therapeutics is a biotechnology company focused on developing next-generation immune-oncology (IO) therapies to improve outcomes for cancer patients. The company's core technology involves a diverse pipeline of targeted antibodies based on nectin pathways, designed to overcome tumor-deployed inhibitory mechanisms and enable immune cells to destroy cancer cells effectively. Additionally, it develops CAR-T and -NK drivers that specifically target tumor cells in various indications, including hard-to-treat cancers. Nectin Therapeutics serves the pharmaceutical and healthcare industries, particularly focusing on oncology and immunology.
Strategic signal
In June 2026, Nectin Therapeutics reported encouraging Phase 1 results for NTX1088 in combination with KEYTRUDA (pembrolizumab) at ASCO 2026. This positive clinical data validates the potential of their lead anti-PVR targeted immunotherapy, signaling significant progress in their pipeline and offering a strong indicator of future development and potential market impact for investors in the oncology space.
Log in to access full profile ›Company Intelligence Q&A
- What clinical trial progress has Nectin Therapeutics announced recently?
- In June 2026, Nectin Therapeutics reported encouraging Phase 1 results for NTX1088 in combination with KEYTRUDA (pembrolizumab) at ASCO 2026, indicating positive advancements in their clinical development.
- Which investor participated in Nectin Therapeutics' funding round in May 2023?
- In May 2023, Myeloma Investment Fund invested in.
- What was the collaboration announced by Nectin Therapeutics in February 2023?
- In February 2023, Nectin Therapeutics announced a collaboration with Merck on a clinical trial for their anti-PVR antibody NTX1088 in combination with KEYTRUDA (pembrolizumab) for patients with locally advanced and metastatic solid tumors.
- Which investors led the December 2022 funding round for Nectin Therapeutics?
- In December 2022, Nectin Therapeutics secured funding with.